PRGO

Pharma, Biotech and How to Consider Investing In It

by

The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. If you cannot view the podcast below, please view the transcript below or select the link here. Tickerized for holdings in the XLV and IBB. Brian Nelson, CFA Gilead’s (GILD) hepatitis C regimen, almost a hundred thousand dollars. Vertex’s (VRTX) cystic fibrosis drug — hundreds of thousands of dollars per year. Have the drug companies lost their mind? This is Brian Nelson from Valuentum Securities, and today joining me is Mr. Kris Rosemann and Mr. Chris Araos — and we are going to talk everything healthcare, biotech… Mr. … Read more

Recent M&A Activity

by

Amid the recent market volatility, firms have remained active in M&A. Let’s take a closer look at what companies will be joining forces. DENTSPLY and Sirona to Join Forces DENTSPLY (XRAY) and Sirona Dental Systems (SIRO) announced September 15 that they have entered an all-stock merger agreement. The resulting company will be the world’s largest manufacturer of professional dental products and technologies. Under the proposed agreement, Sirona shareholders will receive ~1.8 shares of DENTSPLY for each existing Sirona share. If the transaction receives regulatory and shareholder approval, it is expected to close in the first quarter of 2016, and the combined company expects the merger to be accretive to adjusted earnings per share for both companies’ shareholders in the first … Read more

Teva Pharmaceuticals Committed to Acquiring Mylan

by

Image source: Teva July 5 investor presentation We have been adamant on our stance on Best Ideas Newsletter portfolio holding Teva Pharmaceuticals (TEVA) since the initiation of our thesis on the generics industry in June 2013, shortly before we initiated our position in the firm. Since then shares have advanced nearly 50%, and we’ve continued to let this winner run.   A large portion of Teva’s success has been tied to the incredible performance of Copaxone, the leading multiple sclerosis therapy worldwide. In the first quarter of 2015, the drug alone comprised 18.5% of revenue, while contributing an astounding ~55% of net income. These figures are down from the year-ago period–and the majority of its production life–due in part to … Read more

Mylan’s Deal for Perrigo Boosts Teva

by

Image Source: epSos .de We outlined the case on Best Ideas portfolio holding Teva (TEVA) in our generics industry thesis here. The company was added to the portfolio July 24, 2013 at $41.22 per share. Teva Pharma’s shares are now trading north of $66 each, converging to our fair value estimate in just less than two years. With valuations stretched throughout much of our coverage universe, we’re going to continue to let this winner run. Driving the firm higher April 8 was news of Mylan’s (MYL) bid for Perrigo (PRGO) at a significant premium to the latter’s share price. Under the conditions of the non-binding proposal, Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for … Read more

Hooray! Biogen’s Breakthrough Alzheimer’s Drug?

by

We’re disappointed that we missed highlighting Biogen (BIIB) to our membership many moons ago. Biogen’s stock has more than quadrupled since we launched coverage of the company in late 2011, and frankly, its stock has done nothing but rocket higher. To be fair, Biogen is a top-10 holding in the Health Care Select Sector SPDR (XLV), a position in the Best Ideas portfolio, so we do have some exposure to the blossoming biotech, but we could have done a better job pounding the table. The once- 9-rated on the Valuentum Buying Index, Health Care Select Sector SPDR has approximately doubled since it was added to the Best Ideas portfolio, but we know that may not be good enough. The news … Read more

Dividend Increases/Decreases for the Week Ending January 30

by

Let’s take a look at dividend increases/decreases for the week ending January 30.

Stock Market Outlook for 2021

by

By Valuentum Analysts February 8, 2021 2020 was one for the history books. We covered our thoughts and reflections on the past year in our “2020 Won’t Soon Be Forgotten” article (link here), and now we are looking towards the future. Global health authorities should be able to bring an end to the ongoing coronavirus (‘COVID-19’) pandemic sooner than many had expected as several vaccines have already been improved for emergency use and several others appear increasingly likely to get approved. Global vaccine distribution activities are currently underway, and this should allow the world to slowly return to pre-pandemic activities. Before then, immense stimulus measures launched primarily in developed nations should support global economic activities until the public health crisis … Read more

Dividend Increases/Decreases for the Week February 26

by

Below we provide a list of firms that raised their dividends during the week ending February 26. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Acushnet (GOLF): now $0.165 per share quarterly dividend, was $0.155. Alamos Gold (AGI): now $0.025 per share quarterly dividend, was $0.02. Albemarle (ALB): now $0.39 per share quarterly dividend, was $0.385. Allstate (ALL): now $0.81 per share quarterly dividend, was $0.54. Alumina (AWCMF): now $0.029 per share semi-annual dividend, was $0.028. American Homes 4 Rent (AMH): now $0.10 per share quarterly dividend, was $0.05. AMERISAFE (AMSF): … Read more

The Best Years Are Ahead

by

By Brian Nelson, CFA — The wind is at our backs. — The Federal Reserve, Treasury, and regulatory bodies of the U.S. may have no choice but to keep U.S. markets moving higher. The likelihood of the S&P 500 reaching 2,000 ever again seems remote, and I would not be surprised to see 5,000 on the S&P 500 before we see 2,500-3,000, if the latter may be in the cards. The S&P 500 is trading at ~4,100 at the time of this writing. — The high end of our fair value range on the S&P 500 remains just shy of 4,000, but I foresee a massive shift in long-term capital out of traditional bonds into equities this decade (and markets … Read more

Dividend Increases/Decreases for the Week February 18

by

Below we provide a list of firms that raised their dividends during the week ending February 18. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Acadia Realty Trust (AKR): now $0.18 per share quarterly dividend, was $0.15. Advance Auto Parts (AAP): now $1.50 per share quarterly dividend, was $1.00. AEGON (AEG): now EUR 0.09 per share semi-annual dividend, was EUR 0.08. AllianceBernstein (AB): now $1.29 per share quarterly dividend, was $0.89. Allstate (ALL): now $0.85 per share quarterly dividend, was $0.81. American Homes 4 Rent (AMH): now $0.18 per share quarterly … Read more